Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

David E. Goel

At a glance: David E. Goel is 10% Owner at Zentalis Pharmaceuticals (ZNTL). Their latest SEC Form 4, filed Dec 15, 2025, reported a sale of $10.0M. On file: 0 purchase lines ($0) and 1 sale line ($10.0M).

Disclosed holdings: about $8.5M of ZNTL stock: 6,459,973 shares (including shares held indirectly, e.g. through a trust or fund) reported on their latest Form 4 (filed Dec 15, 2025), valued at the Nov 19, 2026 close of $1.31. This counts only ZNTL shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

10% Owner at Zentalis Pharmaceuticals, Inc. (ZNTL)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $10.0M

David E. Goel's InsiderPrint

2 trades from SEC Form 4 filings, 2021 to 2025, drawn as one fingerprint.

InsiderPrint of David E. Goel: 2 trades, 2021 to 20252021: 1 buy, 0 sales2022: 0 buys, 0 sales2023: 0 buys, 0 sales2024: 0 buys, 0 sales2025: 0 buys, 1 sale
  • Bump outward: a purchase (1)
  • Dent inward: a sale (1)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Reported trades

Filed Stock Type Shares Price Value Since
Dec 15SEC ZNTLZentalis Pharmaceuticals, Inc. Sell 7,500,0006,459,973 held (−54%) $1.33 $10.0M -1.5%
  • Sell

    10% Owner David E. Goel sold $10.0M of ZNTL at $1.33 — cuts the stake by 54%.

Follow David E. Goel

Get one email when David E. Goel files a new purchase or sale. Free.

At most one email a day about David E. Goel, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.